Methods for the administration of iloperidone
OwnerCurt Wolfgang, Mihael Polymeropoulos +2inventors
InventorsCurt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
Claims37
A method for treating a patient with an active pharmaceutical ingredient including at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone, comprising the steps of:
- determining the patient's CYP2D6 genotype;
- and
- administering to the patient an effective amount of the active pharmaceutical ingredient, whereby the amount of the active pharmaceutical ingredient is determined based on the patient's CYP2D6 genotype.
A method for treating a patient who is a CYP2D6 poor metabolizer with a pharmaceutically active ingredient including at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone, wherein the patient is administered a lower dosage than would be given to an individual who is not a CYP2D6 poor metabolizer.
A method of treating a patient with a pharmaceutically active ingredient including at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone comprising the steps of:
- determining whether the patient is being administered a CYP2D6 inhibitor;
- and
- reducing the dosage of drug if the patient is being administered a CYP2D6 inhibitor.
A method for determining a patient's CYP2D6 phenotype comprising the steps of:
- administering to the patient a quantity of at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone;
- and
- determining a first concentration of at least one of iloperidone and an iloperidone metabolite in the patient's blood.
A method for determining whether a patient is at risk for prolongation of his or her QTc interval due to administration of at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone comprising the steps of:
- measuring a first QTc interval;
- administering to the patient a quantity of at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone
- measuring a second QTc interval;
- and
- comparing the first and second QTc interval.
Dependencies are inferred from the claim text.